drugset / Trial / NCT01267188
Efficacy and Safety of NBI-98854 in Subjects With Tardive Dyskinesia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to assess the safety and efficacy of three doses (12.5, 25, and 50 mg) of NBI-98854 for the treatment of the symptoms of tardive dyskinesia (TD) in subjects with schizophrenia or schizoaffective disorder.
Timeline
- Start
- 2011-01
- Primary completion
- 2011-03
- Completion
- 2011-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Valbenazine | Small molecule | 50 mg | — |